Physician profile
Peter E Diedrichsen
NPI 1194702597
$1,277.89
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.31 · 2020: $78.39 · 2021: $264 · 2022: $505 · 2023: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $343.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $343.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $329.58 | 2022-2023 | Lumigan, Alphagan P, Vuity |
| Rxsight INC | $327.16 | 2022-2023 | Rxsight Injector Handpiece, Rxsight Injector Cartridge, Rxsight Light Adjustable Lens (Rxlal) |
| Allergan, INC. | $217.65 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $107.99 | 2020-2023 | Cequa |
| Genentech USA, INC. | $56.33 | 2022-2023 | Vabysmo |
| Alcon Vision LLC | $55.44 | 2019-2023 | Precision 1 |
| Aerie Pharmaceuticals, INC. | $42.96 | 2020-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $32.62 | 2019 | |
| Sight Sciences, INC. | $17.99 | 2021 | |
| Rayner Intraocular Lenses Limited | $17.92 | 2023 | Rayone Aspheric, Omidria, Rayone Emv |
| Dompe US, INC. | $16.83 | 2022 | |
| Novartis Pharmaceuticals Corporation | $16.67 | 2021 | |
| Oyster Point Pharma, INC. | $15.67 | 2022 | |
| Apellis Pharmaceuticals, INC. | $13.65 | 2023 | Syfovre |
| The Cameron-Ehlen Group, INC. | $9.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Diedrichsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.